CIK 0001384101 · Large accelerated filer
VERACYTE, INC.
Sign in to watch- Ticker
- VCYT
- Exchange
- Nasdaq
- Industry
- Services-Medical Laboratories
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 205455398
- Phone
- (650) 243-6300
- Business address
- 6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA, 94080
- Former names
- CALDEROME INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $2,858,989
- in 9 filings, $2.9M under 10b5-1 plans
Net −$2,858,989. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-11-05 | McGuire Annie SVP, General Counsel | Sale 10b5-1 | −6,466 | $40.00 | $259K | 82,973 |
| 2025-11-05 | Chambers Rebecca Chief Financial Officer | Sale 10b5-1 | −7,000 | $41.00 | $287K | 126,158 |
| 2025-11-05 | EASTHAM KARIN Director | Sale 10b5-1 | −9,674 | $40.02 | $387K | 13,554 |
| 2025-11-05 | JONES EVAN/ FA Director | Option exercise 10b5-1 | +10,000 | $5.28 | $53K | 53,664 |
| 2025-11-05 | JONES EVAN/ FA Director | Option exercise 10b5-1 | +10,000 | $7.94 | $79K | 63,664 |
| 2025-11-05 | JONES EVAN/ FA Director | Option exercise 10b5-1 | +10,000 | $7.60 | $76K | 73,664 |
| 2025-11-05 | JONES EVAN/ FA Director | Sale 10b5-1 | −408 | $41.74 | $17K | 73,256 |
| 2025-11-05 | JONES EVAN/ FA Director | Sale 10b5-1 | −1,126 | $43.03 | $48K | 72,130 |
| 2025-11-05 | JONES EVAN/ FA Director | Sale 10b5-1 | −10,837 | $43.80 | $475K | 61,293 |
| 2025-11-05 | JONES EVAN/ FA Director | Sale 10b5-1 | −5,872 | $45.07 | $265K | 55,421 |
| 2025-11-05 | JONES EVAN/ FA Director | Sale 10b5-1 | −24,296 | $45.73 | $1.1M | 31,125 |
| 2025-11-05 | JONES EVAN/ FA Director | Sale 10b5-1 | −657 | $46.38 | $30K | 30,468 |
| 2025-11-05 | JONES EVAN/ FA Director | Option exercise · Stock Option (right to buy) 10b5-1 | −10,000 | 0 | ||
| 2025-11-05 | JONES EVAN/ FA Director | Option exercise · Stock Option (right to buy) 10b5-1 | −10,000 | 0 | ||
| 2025-11-05 | JONES EVAN/ FA Director | Option exercise · Stock Option (right to buy) 10b5-1 | −10,000 | 0 | ||
| 2025-10-28 | Wygant Jonathan VP, Chief Accounting Officer | Grant or award | +2,886 | 49,665 | ||
| 2025-10-06 | Febbo Phillip G. Chief Scientific & Med Officer | Sale 10b5-1 | −8,349 | $36.02 | $301K | 92,441 |
| 2025-10-01 | Leite John Chief Commercial Officer-CLIA | Sale 10b5-1 | −2,539 | $35.00 | $89K | 89,099 |
| 2025-10-01 | McGuire Annie SVP, General Counsel | Sale 10b5-1 | −2,160 | $35.00 | $76K | 89,439 |
| 2025-10-01 | EPSTEIN ROBERT S Director | Option exercise 10b5-1 | +10,000 | $7.94 | $79K | 83,919 |
Page 7 of 9 · 168 trades